Treatment of Raynaud's phenomenon with the 5-HT2-receptor antagonist ketanserin.
The selective 5-hydroxytryptamine2-(5-HT2)-receptor-blocking agent ketanserin was given in a dose of 10 mg intravenously to nine patients with Raynaud's phenomenon. The effect on blood flow was assessed by photopletysmography and measurments of skin temperature. Digital blood flow and skin temperature increased significantly after ketanserin injection, whereas the placebo (saline 9 g/l) had no such effect. This study suggests that ketanserin may be useful in the treatment of Raynaud's phenomenon.
D000328:Adult; D000368:Aged; D005260:Female; D005385:Fingers / Q000098:blood supply; D006801:Humans; D007650:Ketanserin; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000627:therapeutic use*; D011928:Raynaud Disease / Q000188:drug therapy*; D012039:Regional Blood Flow / Q000187:drug effects; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D012881:Skin Temperature / Q000187:drug effects
D010880:Piperidines; D012702:Serotonin Antagonists; D007650:Ketanserin